Research Paper Volume 13, Issue 24 pp 26046—26062

An immune-related lncRNA risk coefficient model to predict the outcomes in clear cell renal cell carcinoma


Figure 10. Correlation analysis of immune-targeted drugs in patients with ccRCC. The risk factor score was used as a potential predictor. Compared with the low-risk group, the sunitinib IC50 value of high-risk patients was lower (A), which was statistically significant (P = 3e-08). Axitinib (B), bevacizumab (C), and pazopanib (D), and sorafenib (E) were not significantly different between the high- and low-risk groups.